Clinical Trials on Neovascular Age-Related Macular Degeneration in United States

Total 2686 results

Retina Macula Institute

Completed

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Duke University
Bausch & Lomb Incorporated

Completed

Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD

Neovascular Age-Related Macular Degeneration

United States
Ocugenix Corporation

Not yet recruiting

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration (nAMD)

United States
Novartis Pharmaceuticals

Completed

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Regeneron Pharmaceuticals

Completed

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

Neovascular Age Related Macular Degeneration

United States
Johns Hopkins University

Completed

NVAMD Satellite Study

Neovascular Age Related Macular Degeneration

United States
Iconic Therapeutics, Inc.

Completed

Safety and Tolerability Study for Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Ocular Therapeutix, Inc.
Duke University; Fortrea

Recruiting

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Sandoz

Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Neovascular Age-related Macular Degeneration (nAMD)

United States
University of Miami
Genentech, Inc.

Completed

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

Neovascular Age-Related Macular Degeneration

United States
Ocular Therapeutix, Inc.

Completed

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Apellis Pharmaceuticals, Inc.

Completed

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD (ASAP II)

Neovascular Age-Related Macular Degeneration

United States, Australia
Sequenom, Inc.

Completed

Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

Age-related Macular Degeneration | Choroidal Neovascular Age-related Macular Degeneration

United States
Retinal Consultants of Arizona
Ophthotech Corporation

Completed

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Sandoz

Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Neovascular Age-related Macular Degeneration (nAMD)

United States
Vitreous -Retina- Macula Consultants of New York

Unknown

Intense Treatment Regimen With Intravitreal Aflibercept Injection (I-TRAP)

Neovascular Age-Related Macular Degeneration

United States
Aerie Pharmaceuticals
Alcon Research

Recruiting

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)

Neovascular Age-related Macular Degeneration (nAMD)

United States
David M. Brown, M.D.
Genentech, Inc.

Terminated

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial) (SAVE)

Macular Degeneration | Age Related Macular Degeneration | Wet Age-Related Macular Degeneration | Choroidal Neovascular Membrane | Subfoveal Neovascular Age-Related Macular Degeneration

United States
Lpath, Inc.

Unknown

Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Graybug Vision

Completed

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
Hoffmann-La Roche

Completed

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

Neovascular Age-Related Macular Degeneration

United States
Hoffmann-La Roche

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal) (Portal)

Neovascular Age-Related Macular Degeneration

Belgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
Regeneron Pharmaceuticals

Terminated

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

Neovascular Age-Related Macular Degeneration

United States, Japan
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)

United States, Japan, Korea, Republic of, Australia
Retinal Consultants of Arizona
Genentech, Inc.

Completed

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) (Liberty)

Neovascular Age Related Macular Degeneration

United States
Hoffmann-La Roche

Recruiting

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Neovascular Age-related Macular Degeneration (nAMD)

Belgium, Korea, Republic of, Germany, Spain, United Kingdom, Australia, Italy, Argentina, Israel, Austria, Brazil, France, Singapore, Switzerland, Taiwan, Turkey
Notal Vision Inc.

Completed

Single In-Clinic Encounter With the Notal Vision Home OCT

Neovascular Age-related Macular Degeneration | Intermediate Age Related Macular Degeneration (Disorder)

United States
Regeneron Pharmaceuticals

Active, not recruiting

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Diabetic Macular Edema (DME) | Neovascular Age-Related Macular Degeneration (nAMD)

United States
Tennessee Retina
Regeneron Pharmaceuticals

Unknown

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept (TRISTAR)

Neovascular Age-related Macular Degeneration

United States
Notal Vision Inc.

Completed

Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study

Neovascular Age-related Macular Degeneration

United States
AiViva BioPharma, Inc.

Completed

Effect of Intravitreally Administered AIV007 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

United States
Oregon Health and Science University

Completed

Neovascular Age-related Macular Degeneration (NVAMD)

Neovascular Age-related Macular Degeneration

United States
Duke University
Bausch & Lomb Incorporated

Withdrawn

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

Neovascular Age-related Macular Degeneration

United States
REGENXBIO Inc.

Completed

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
AbbVie
AbbVie

Enrolling by invitation

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Gene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMD

United States
Notal Vision Inc.

Recruiting

Home OCT Fluid Visualization Agreement Study

Neovascular Age-related Macular Degeneration

United States
Clearside Biomedical, Inc.

Completed

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Neovascular Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Neovascular (Wet) Age-related Macular Degeneration

United States
Notal Vision Inc.

Completed

The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT

Neovascular Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

Neovascular Age-related Macular Degeneration

United States
Apellis Pharmaceuticals, Inc.

Terminated

Pegcetacoplan (APL-2) in Neovascular AMD

Neovascular Age-related Macular Degeneration

United States
AsclepiX Therapeutics, Inc.

Active, not recruiting

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) (DISCOVER)

Neovascular Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Terminated

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Neovascular Age-related Macular Degeneration

United States
Exegenesis Bio

Recruiting

A Study of EXG102-031 in Patients With wAMD (Everest)

Neovascular (Wet) Age-related Macular Degeneration (nAMD)

United States
Olix Pharmaceuticals, Inc.
Trial Runners, LLC

Recruiting

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

United States
AffaMed Therapeutics (US) Inc.

Recruiting

Safety and Efficacy of AM712 in Patients With nAMD

Neovascular Age-related Macular Degeneration

United States
University of Miami

Completed

An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

Neovascular Age-related Macular Degeneration

United States
EyeBiotech Ltd.

Recruiting

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (NVAMD)

United States, Argentina, Puerto Rico, United Kingdom

Clinical Trials on Neovascular Age-Related Macular Degeneration in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations